Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the quick ratio (acid-test) high or low?
The quick ratio (acid-test) of 24.16 is 172% above its 3-year average of 8.90, near the high end of its 3-year range (0.00–24.16).
As of the fiscal period ended Tuesday, June 30, 2026. 81.88% above its 12-month average of 13.28.
Reported quarterly quick ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 24.16.
QUICK RATIO (ACID-TEST)
24.16
QUICK RATIO (ACID-TEST) AVG TTM
13.28
QUICK RATIO (ACID-TEST) AVG 3Y
9.58
QUICK RATIO (ACID-TEST) AVG 5Y
N/A
QUICK RATIO (ACID-TEST) AVG 10Y
N/A
QUICK RATIO (ACID-TEST) AVG 15Y
N/A
QUICK RATIO (ACID-TEST) AVG 20Y
N/A
CURRENT VS TTM AVG
+81.88%
CURRENT VS 3Y AVG
+152.18%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
3.19
median of 762 covered companies
CURRENT VS SECTOR MEDIAN
+657.36%
vs the sector median at left
Artiva Biotherapeutics, Inc.
Market Cap
$354.45M
Quick Ratio (Acid-Test)
24.16
TTM Avg
13.28
3Y Avg
9.58
5Y Avg
N/A
Market Cap
$355.36M
Quick Ratio (Acid-Test)
5.66
TTM Avg
6.21
3Y Avg
5.34
5Y Avg
8.05
Market Cap
$353.30M
Quick Ratio (Acid-Test)
29.52
TTM Avg
9.54
3Y Avg
9.83
5Y Avg
10.59
Market Cap
$359.33M
Quick Ratio (Acid-Test)
3.76
TTM Avg
4.71
3Y Avg
6.65
5Y Avg
8.92
Market Cap
$359.53M
Quick Ratio (Acid-Test)
1.68
TTM Avg
1.66
3Y Avg
1.70
5Y Avg
1.47
Market Cap
$349.40M
Quick Ratio (Acid-Test)
8.24
TTM Avg
5.34
3Y Avg
5.79
5Y Avg
4.44
Market Cap
$363.54M
Quick Ratio (Acid-Test)
12.19
TTM Avg
4.83
3Y Avg
10.20
5Y Avg
8.85
Market Cap
$374.75M
Quick Ratio (Acid-Test)
2.39
TTM Avg
2.24
3Y Avg
1.74
5Y Avg
3.80
| NAME | MARKET CAP | QUICK RATIO (ACID-TEST) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Artiva Biotherapeutics, Inc. (ARTV) | $354.45M | 24.16 | 13.28 | 9.58 | N/A |
| Fennec Pharmaceuticals Inc. (FENC)vs › | $355.36M | 5.66 | 6.21 | 5.34 | 8.05 |
| Relmada Therapeutics, Inc. (RLMD)vs › | $353.30M | 29.52 | 9.54 | 9.83 | 10.59 |
| Enanta Pharmaceuticals, Inc. (ENTA)vs › | $359.33M | 3.76 | 4.71 | 6.65 | 8.92 |
| Ocugen, Inc. (OCGN)vs › | $359.46M | 0.80 | 1.96 | 2.47 | 5.28 |
| Embecta Corp. (EMBC)vs › | $359.53M | 1.68 | 1.66 | 1.70 | 1.47 |
| Orchestra BioMed Holdings, Inc. (OBIO)vs › | $349.40M | 8.24 | 5.34 | 5.79 | 4.44 |
| Opus Genetics, Inc. (IRD)vs › | $363.54M | 12.19 | 4.83 | 10.20 | 8.85 |
| Canopy Growth Corporation (CGC)vs › | $374.75M | 2.39 | 2.24 | 1.74 | 3.80 |
| Agenus Inc. (AGEN)vs › | $332.29M | 0.34 | 0.31 | 0.53 | 0.83 |
Quick Ratio
24.16
Excludes inventory
Current Ratio
24.16
Includes inventory
Quick Ratio = (Current Assets − Inventory) / Current Liabilities
The quick ratio is a stricter liquidity measure that excludes inventory, showing the ability to meet short-term obligations with the most liquid assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | QUICK RATIO (ACID-TEST) |
|---|---|
| 2026-06-30 | 24.16 |
| 2026-03-31 | 8.16 |
| 2025-12-31 | 8.61 |
| 2025-09-30 | 11.65 |
| 2025-06-30 | 13.84 |
| 2025-03-31 | 13.93 |
| 2024-12-31 | 15.39 |
| 2024-09-30 | 11.33 |
| 2024-06-30 | 4.59 |
| 2024-03-31 | 6.35 |
| 2023-12-31 | 6.53 |
| 2023-09-30 | 0.00 |
| 2023-06-30 | 0.00 |
| 2023-03-31 | 0.00 |
